X0202 SCHEDULE 13D/A 0001193125-17-012367 0001694903 XXXXXXXX LIVE 2 COMMON STOCK 07/31/2026 0001133416 363225202 GALECTIN THERAPEUTICS INC

4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071

Richard E. Uihlein 262-612-4200 12575 Uline Drive Pleasant Prairie WI 53158 0001694903 N Richard E. Uihlein PF X1 54673646 54673646 54673646 49.30 IN COMMON STOCK GALECTIN THERAPEUTICS INC 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 Richard E. Uihlein 12575 Uline Drive, Pleasant Prairie, WI 53158 None None None United States Personal Funds The Shares were acquired for investment purposes and were not acquired with the purpose or effect of changing or influencing control of the Company. 54,673,646 shares of common stock, which includes 44,736,553 shares of common stock and 9,937,093 shares of common stock issuable upon conversion of warrants, options, and other convertible securities). The Reporting Person's aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%. 54,673,646 shares of common stock, which includes 44,736,553 shares of common stock and 9,937,093 shares of common stock issuable upon conversion of warrants, options, and other convertible securities). The Reporting Person's aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%. On July 31, 2026, the Reporting person converted debt in the amount of approximately $105.8 (consitsing of $91.0 million of principal and approximately $14.8 million of accrued interest) into 34,376,167 shares of common stock. None None None Richard E. Uihlein /s/ Richard E. Uihlein 08/04/2026